Quoc Le-Nguyen
Technik-/Wissenschafts-/F&E-Leiter bei 89BIO, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Quoc Le-Nguyen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
89BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2019 | - |
Karriereverlauf von Quoc Le-Nguyen
Ehemalige bekannte Positionen von Quoc Le-Nguyen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01.09.2015 | 01.07.2018 |
BAYER AG | Corporate Officer/Principal | 01.09.2007 | 01.09.2013 |
Ausbildung von Quoc Le-Nguyen
University of California | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Deutschland | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
89BIO, INC. | Health Technology |
BAYER AG | Health Technology |
Private Unternehmen | 1 |
---|---|
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Quoc Le-Nguyen
- Erfahrung